Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT03396926, this PHASE2 trial focuses on Microsatellite Stable and Mismatch Repair Protein Proficient and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 16 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
16 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
May 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 11 earlier versions
-
Jun 2022 — May 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Jun 2022 [monthly]
Recruiting PHASE2
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Mar 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Apr 2020 — Sep 2020 [monthly]
Recruiting PHASE2
-
Jun 2019 — Apr 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2018 — May 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .